Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 19, Issue 47, 2013, Pages 8831-8849

  Bacigalupo, María L ^a   Manzi, Malena ^a   Rabinovich, Gabriel A ^b   Troncoso, María F ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

Author keywords

Fibrosis related liver pathologies; Galectins; Hepatitis B or C virus infection associated hepatocellular carcinoma; Hepatocellular carcinoma; Inflammation associated liver injury

Indexed keywords

ECALECTIN; GALECTIN; GALECTIN 1; GALECTIN 3; GALECTIN 4; GALECTIN 8; KIDNEY INJURY MOLECULE 1; MUCIN 1; PROTEOME;

ARTICLE; CELL INVASION; CELL MIGRATION; DNA METHYLATION; GENE; GENE OVEREXPRESSION; HEPATITIS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LGALS3 GENE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; MALIGNANT TRANSFORMATION; METASTASIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR RECURRENCE;

FIBROSIS-RELATED LIVER PATHOLOGIES; GALECTINS; HEPATITIS B OR C VIRUS INFECTION-ASSOCIATED HEPATOCELLULAR CARCINOMA; HEPATOCELLULAR CARCINOMA; INFLAMMATION-ASSOCIATED LIVER INJURY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; DRUG DESIGN; GALECTINS; HEPATITIS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION;

EID: 84890940208     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i47.8831     Document Type: Article

References (198)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]
2. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vec-chia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 2008; 48: 137-145 [PMID: 18537177 DOI: 10.1002/hep.22312]
3. Qiu D, Katanoda K, Marugame T, Sobue T. A Joinpoint regression analysis of long-term trends in cancer mortality in Japan (1958-2004). Int J Cancer 2009; 124: 443-448 [PMID: 18844218 DOI: 10.1002/ijc.23911]
4. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127 [PMID: 21992124 DOI: 10.1056/NEJM-ra1001683]
5. Farazi PA, DePinho RA. Hepatocellular carcinoma patho-genesis: from genes to environment. Nat Rev Cancer 2006; 6: 674-687 [PMID: 16929323 DOI: 10.1038/nrc1934]
6. But DY, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol 2008; 14: 1652-1656 [PMID: 18350595 DOI: 10.3748/wjg.14.1652]
7. El-Serag HB. Epidemiology of viral hepatitis and hepato-cellular carcinoma. Gastroenterology 2012; 142: 1264-1273.e1 [PMID: 22537432 DOI: 10.1053/j.gastro.2011.12.061]
8. Zhang DY, Friedman SL. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology 2012; 56: 769-775 [PMID: 22378017 DOI: 10.1002/hep.25670]
9. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012; 56: 1384-1391 [PMID: 22326465 DOI: 10.1016/ j.jhep.2011.10.027]
10. Yu J, Shen J, Sun TT, Zhang X, Wong N. Obesity, insulin resistance, NASH and hepatocellular carcinoma. Semin Cancer Biol 2013; 23: 483-491 [PMID: 23876851 DOI: 10.1016/ j.semcancer.2013.07.003]
11. Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol 2013; 10: 34-42 [PMID: 23147664 DOI: 10.1038/nrgastro.2012.199]
12. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatol 2012; 56 Suppl 1: S75-S87 [PMID: 22300468 DOI: 10.1016/S0168-8278(12)60009-9]
13. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255 [PMID: 22353262 DOI: 10.1016/ S0140-6736(11)61347-0]
14. Mancuso A. Management of hepatocellular carcinoma: Enlightening the gray zones. World J Hepatol 2013; 5: 302-310 [PMID: 23805354 DOI: 10.4254/wjh.v5.i6.302]
15. Yamamoto J, Kosuge T, Takayama T, Shimada K, Yama-saki S, Ozaki H, Yamaguchi N, Makuuchi M. Recurrence of hepatocellular carcinoma after surgery. Br J Surg 1996; 83: 1219-1222 [PMID: 8983610]
16. Ercolani G, Grazi GL, Ravaioli M, Del Gaudio M, Gardini A, Cescon M, Varotti G, Cetta F, Cavallari A. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg 2003; 237: 536-543 [PMID: 12677151 DOI: 10.1097/01.SLA.0000059988.22416.F2]
17. Vivarelli M, Risaliti A. Liver transplantation for hepato-cellular carcinoma on cirrhosis: strategies to avoid tumor recurrence. World J Gastroenterol 2011; 17: 4741-4746 [PMID: 22147974 DOI: 10.3748/wjg.v17.i43.4741]
18. Pang RW, Poon RT. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 2007; 72 Suppl 1: 30-44 [PMID: 18087180 DOI: 10.1159/000111705]
19. Llovet JM, Bruix J. Molecular targeted therapies in hepato-cellular carcinoma. Hepatology 2008; 48: 1312-1327 [PMID: 18821591 DOI: 10.1002/hep.22506]
20. Shen YC, Hsu C, Cheng AL. Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol 2010; 45: 794-807 [PMID: 20567987 DOI: 10.1007/s00535-010-0270-0]
21. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]
22. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Ef-fcacy and safety of sorafenib in patients in the Asia-Pacifc region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34 [PMID: 19095497 DOI: 10.1016/ S1470-2045(08)70285-7]
23. Matar P, Alaniz L, Rozados V, Aquino JB, Malvicini M, Atorrasagasti C, Gidekel M, Silva M, Scharovsky OG, Maz-zolini G. Immunotherapy for liver tumors: present status and future prospects. J Biomed Sci 2009; 16: 30 [PMID: 19272130 DOI: 10.1186/1423-0127-16-30]
24. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes C, Kasai K, Leffer H, Liu F, Lotan R, Mercurio AM, Monsigny M, Pillai S, Poirier F, Raz A, Rigby PWJ, Rini JM, Wang JL. Galectins: a family of animal beta-galactoside-binding lec-tins. Cell 1994; 76: 597-598 [PMID: 8124704]
25. Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins. Structure and function of a large family of animal lectins. J Biol Chem 1994; 269: 20807-20810 [PMID: 8063692]
26. Yang RY, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 2008; 10: e17 [PMID: 18549522 DOI: 10.1017/S1462399408000719]
27. Chiariotti L, Salvatore P, Frunzio R, Bruni CB. Galectin genes: regulation of expression. Glycoconj J 2004; 19: 441-449 [PMID: 14758067 DOI: 10.1023/B:GLYC.0000014073.23096.3a]
28. Camby I, Le Mercier M, Lefranc F, Kiss R. Galectin-1: a small protein with major functions. Glycobiology 2006; 16: 137R-157R [PMID: 16840800 DOI: 10.1093/glycob/cwl025]
29. Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta 2006; 1760: 616-635 [PMID: 16478649 DOI: 10.1016/j.bbagen.2005.12.020]
30. Cooper DN, Barondes SH. God must love galectins; he made so many of them. Glycobiology 1999; 9: 979-984 [PMID: 10521533]
31. Hughes RC. Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim Biophys Acta 1999; 1473: 172-185 [PMID: 10580137]
32. Nickel W. Unconventional secretory routes: direct protein export across the plasma membrane of mammalian cells. Traffic 2005; 6: 607-614 [PMID: 15998317 DOI: 10.1111/ j.1600-0854.2005.00302.x]
33. Cooper DN, Barondes SH. Evidence for export of a muscle lectin from cytosol to extracellular matrix and for a novel secretory mechanism. J Cell Biol 1990; 110: 1681-1691 [PMID: 2335567]
34. Lindstedt R, Apodaca G, Barondes SH, Mostov KE, Leffer H. Apical secretion of a cytosolic protein by Madin-Darby canine kidney cells. Evidence for polarized release of an endogenous lectin by a nonclassical secretory pathway. J Biol Chem 1993; 268: 11750-11757 [PMID: 8505302]
35. Sato S, Burdett I, Hughes RC. Secretion of the baby hamster kidney 30-kDa galactose-binding lectin from polarized and nonpolarized cells: a pathway independent of the endoplas-mic reticulum-Golgi complex. Exp Cell Res 1993; 207: 8-18 [PMID: 8319774 DOI: 10.1006/excr.1993.1157]
36. Chabot S, Kashio Y, Seki M, Shirato Y, Nakamura K, Nishi N, Nakamura T, Matsumoto R, Hirashima M. Regulation of galectin-9 expression and release in Jurkat T cell line cells. Glycobiology 2002; 12: 111-118 [PMID: 11886844]
37. Oomizu S, Arikawa T, Niki T, Kadowaki T, Ueno M, Nishi N, Yamauchi A, Hattori T, Masaki T, Hirashima M. Cell surface galectin-9 expressing Th cells regulate Th17 and Foxp3+ Treg development by galectin-9 secretion. PLoS One 2012; 7: e48574 [PMID: 23144904 DOI: 10.1371/journal. pone.0048574]
38. Rabinovich GA, Toscano MA, Jackson SS, Vasta GR. Functions of cell surface galectin-glycoprotein lattices. Curr Opin Struct Biol 2007; 17: 513-520 [PMID: 17950594 DOI: 10.1016/ j.sbi.2007.09.002]
39. Garner OB, Baum LG. Galectin-glycan lattices regulate cell-surface glycoprotein organization and signalling. Bio-chem Soc Trans 2008; 36: 1472-1477 [PMID: 19021578 DOI: 10.1042/BST0361472]
40. Laderach DJ, Compagno D, Toscano MA, Croci DO, Der-gan-Dylon S, Salatino M, Rabinovich GA. Dissecting the signal transduction pathways triggered by galectin-glycan interactions in physiological and pathological settings. IUBMB Life 2010; 62: 1-13 [PMID: 20014236 DOI: 10.1002/iub.281]
41. Fajka-Boja R, Blaskó A, Kovács-Sólyom F, Szebeni GJ, Tóth GK, Monostori E. Co-localization of galectin-1 with GM1 ganglioside in the course of its clathrin- and raft-dependent endocytosis. Cell Mol Life Sci 2008; 65: 2586-2593 [PMID: 18581052 DOI: 10.1007/s00018-008-8143-x]
42. Liu FT, Patterson RJ, Wang JL. Intracellular functions of galectins. Biochim Biophys Acta 2002; 1572: 263-273 [PMID: 12223274]
43. Elola MT, Wolfenstein-Todel C, Troncoso MF, Vasta GR, Rabinovich GA. Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci 2007; 64: 1679-1700 [PMID: 17497244 DOI: 10.1007/ s00018-007-7044-8]
44. Liu FT, Rabinovich GA. Galectins: regulators of acute and chronic infammation. Ann N Y Acad Sci 2010; 1183: 158-182 [PMID: 20146714 DOI: 10.1111/j.1749-6632.2009.05131.x]
45. Rabinovich GA, Croci DO. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity 2012; 36: 322-335 [PMID: 22444630 DOI: 10.1016/ j.immuni.2012.03.004]
46. Troncoso MF, Elola MT, Croci DO, Rabinovich GA. Integrating structure and function of 'tandem-repeat' galectins. Front Biosci (Schol Ed) 2012; 4: 864-887 [PMID: 22202096]
47. Lahm H, André S, Hoeflich A, Kaltner H, Siebert HC, Sordat B, Von Der Lieth CW, Wolf E, Gabius HJ. Tumor ga-lectinology: insights into the complex network of a family of endogenous lectins. Glycoconj J 2004; 20: 227-238 [PMID: 15115907 DOI: 10.1023/B: GLYC.0000025817.24297.17]
48. Van Den Brûle F, Califice S, Castronovo V. Expression of galectins in cancer: a critical review. Glycoconj J 2004; 19: 537-542 [PMID: 14758077 DOI: 10.1023/B:GLYC.0000014083.48508.6a]
49. Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer 2005; 5: 29-41 [PMID: 15630413 DOI: 10.1038/nrc1527]
50. Cedeno-Laurent F, Dimitroff CJ. Galectins and their li-gands: negative regulators of anti-tumor immunity. Gly-coconj J 2012; 29: 619-625 [PMID: 22544342 DOI: 10.1007/ s10719-012-9379-0]
51. Compagno D, Laderach DJ, Gentilini L, Jaworski FM, Rabinovich GA. Delineating the "galectin signature" of the tumor microenvironment. Oncoimmunology 2013; 2: e23565 [PMID: 23734312 DOI: 10.4161/onci.23565]
52. Thijssen VL, Rabinovich GA, Griffoen AW. Vascular galec-tins: Regulators of tumor progression and targets for cancer therapy. Cytokine Growth Factor Rev 2013; 24: 547-558 [PMID: 23942184 DOI: 10.1016/j.cytogfr.2013.07.003]
53. Ingrassia L, Camby I, Lefranc F, Mathieu V, Nshimyumuki-za P, Darro F, Kiss R. Anti-galectin compounds as potential anti-cancer drugs. Curr Med Chem 2006; 13: 3513-3527 [PMID: 17168720]
54. Hasan SS, Ashraf GM, Banu N. Galectins - potential targets for cancer therapy. Cancer Lett 2007; 253: 25-33 [PMID: 17207926 DOI: 10.1016/j.canlet.2006.11.030]
55. Ito K, Stannard K, Gabutero E, Clark AM, Neo SY, Onturk S, Blanchard H, Ralph SJ. Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment. Cancer Metastasis Rev 2012; 31: 763-778 [PMID: 22706847 DOI: 10.1007/s10555-012-9388-2]
56. Wiersma VR, de Bruyn M, Helfrich W, Bremer E. Therapeutic potential of Galectin-9 in human disease. Med Res Rev 2013; 33 Suppl 1: E102-E126 [PMID: 21793015 DOI: 10.1002/ med.20249]
57. Danguy A, Camby I, Kiss R. Galectins and cancer. Biochim Biophys Acta 2002; 1572: 285-293 [PMID: 12223276]
58. Rabinovich GA. Galectin-1 as a potential cancer target. Br J Cancer 2005; 92: 1188-1192 [PMID: 15785741 DOI: 10.1038/ sj.bjc.6602493]
59. Martinez VG, Pellizzari EH, Díaz ES, Cigorraga SB, Lustig L, Denduchis B, Wolfenstein-Todel C, Iglesias MM. Galectin-1, a cell adhesion modulator, induces apoptosis of rat Leydig cells in vitro. Glycobiology 2004; 14: 127-137 [PMID: 14638631 DOI: 10.1093/glycob/cwh025]
60. Elola MT, Chiesa ME, Alberti AF, Mordoh J, Fink NE. Ga-lectin-1 receptors in different cell types. J Biomed Sci 2005; 12: 13-29 [PMID: 15864736 DOI: 10.1007/s11373-004-8169-5]
61. Cedeno-Laurent F, Dimitroff CJ. Galectin-1 research in T cell immunity: past, present and future. Clin Immunol 2012; 142: 107-116 [PMID: 22019770 DOI: 10.1016/j.clim.2011.09.011]
62. Balan V, Nangia-Makker P, Raz A. Galectins as Cancer Bio-markers. Cancers (Basel) 2010; 2: 592-610 [PMID: 23658855 DOI: 10.3390/cancers2020592]
63. Lefranc F, Mathieu V, Kiss R. Galectin-1-mediated biochemical controls of melanoma and glioma aggressive behavior. World J Biol Chem 2011; 2: 193-201 [PMID: 21949569 DOI: 10.4331/wjbc.v2.i9.193]
64. Chung LY, Tang SJ, Sun GH, Chou TY, Yeh TS, Yu SL, Sun KH. Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cy-clooxygenase-2. Clin Cancer Res 2012; 18: 4037-4047 [PMID: 22696230 DOI: 10.1158/1078-0432.CCR-11-3348]
65. Laderach DJ, Gentilini LD, Giribaldi L, Delgado VC, Nugnes L, Croci DO, Al Nakouzi N, Sacca P, Casas G, Mazza O, Shipp MA, Vazquez E, Chauchereau A, Kutok JL, Rodig SJ, Elola MT, Compagno D, Rabinovich GA. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Cancer Res 2013; 73: 86-96 [PMID: 23108139 DOI: 10.1158/0008-5472.CAN-12-1260]
66. Verschuere T, Van Woensel M, Fieuws S, Lefranc F, Ma-thieu V, Kiss R, Van Gool SW, De Vleeschouwer S. Altered galectin-1 serum levels in patients diagnosed with high-grade glioma. J Neurooncol 2013; 115: 9-17 [PMID: 23824536 DOI: 10.1007/s11060-013-1201-8]
67. Chen J, Zhou SJ, Zhang Y, Zhang GQ, Zha TZ, Feng YZ, Zhang K. Clinicopathological and prognostic signifcance of galectin-1 and vascular endothelial growth factor expression in gastric cancer. World J Gastroenterol 2013; 19: 2073-2079 [PMID: 23599627 DOI: 10.3748/wjg.v19.i13.2073]
68. Jung EJ, Moon HG, Cho BI, Jeong CY, Joo YT, Lee YJ, Hong SC, Choi SK, Ha WS, Kim JW, Lee CW, Lee JS, Park ST. Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer 2007; 120: 2331-2338 [PMID: 17304502 DOI: 10.1002/ijc.22434]
69. Dalotto-Moreno T, Croci DO, Cerliani JP, Martinez-Allo VC, Dergan-Dylon S, Méndez-Huergo SP, Stupirski JC, Mazal D, Osinaga E, Toscano MA, Sundblad V, Rabinovich GA, Salatino M. Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res 2013; 73: 1107-1117 [PMID: 23204230 DOI: 10.1158/0008-5472.CAN-12-2418]
70. Kim HJ, Do IG, Jeon HK, Cho YJ, Park YA, Choi JJ, Sung CO, Lee YY, Choi CH, Kim TJ, Kim BG, Lee JW, Bae DS. Galectin 1 expression is associated with tumor invasion and metastasis in stage IB to IIA cervical cancer. Hum Pathol 2013; 44: 62-68 [PMID: 22939954 DOI: 10.1016/j.humpath.2012.04.010]
71. Hsu YL, Wu CY, Hung JY, Lin YS, Huang MS, Kuo PL. Ga-lectin-1 promotes lung cancer tumor metastasis by potentiating integrin α6β4 and Notch1/Jagged2 signaling pathway. Carcinogenesis 2013; 34: 1370-1381 [PMID: 23389289 DOI: 10.1093/carcin/bgt040]
72. Thijssen VL, Barkan B, Shoji H, Aries IM, Mathieu V, Del-tour L, Hackeng TM, Kiss R, Kloog Y, Poirier F, Griffoen AW. Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res 2010; 70: 6216-6224 [PMID: 20647324 DOI: 10.1158/0008-5472.CAN-09-4150]
73. Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S, Verhofstad N, Nakabeppu Y, Baum LG, Bakkers J, Mayo KH, Poirier F, Griffoen AW. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 2006; 103: 15975-15980 [PMID: 17043243 DOI: 10.1073/pnas.0603883103]
74. Le QT, Shi G, Cao H, Nelson DW, Wang Y, Chen EY, Zhao S, Kong C, Richardson D, O'Byrne KJ, Giaccia AJ, Koong AC. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 2005; 23: 8932-8941 [PMID: 16219933 DOI: 10.1200/JCO.2005.02.0206]
75. Croci DO, Salatino M, Rubinstein N, Cerliani JP, Cavallin LE, Leung HJ, Ouyang J, Ilarregui JM, Toscano MA, Domai-ca CI, Croci MC, Shipp MA, Mesri EA, Albini A, Rabinovich GA. Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma. J Exp Med 2012; 209: 1985-2000 [PMID: 23027923 DOI: 10.1084/jem.20111665]
76. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilar-regui JM, Bravo A, Mordoh J, Fainboim L, Podhajcer OL, Rabinovich GA. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 2004; 5: 241-251 [PMID: 15050916]
77. Juszczynski P, Ouyang J, Monti S, Rodig SJ, Takeyama K, Abramson J, Chen W, Kutok JL, Rabinovich GA, Shipp MA. The AP1-dependent secretion of galectin-1 by Reed Stern-berg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA 2007; 104: 13134-13139 [PMID: 17670934 DOI: 10.1073/pnas.0706017104]
78. Banh A, Zhang J, Cao H, Bouley DM, Kwok S, Kong C, Giaccia AJ, Koong AC, Le QT. Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res 2011; 71: 4423-4431 [PMID: 21546572 DOI: 10.1158/0008-5472.CAN-10-4157]
79. Chung EJ, Sung YK, Farooq M, Kim Y, Im S, Tak WY, Hwang YJ, Kim YI, Han HS, Kim JC, Kim MK. Gene expression profile analysis in human hepatocellular carcinoma by cDNA microarray. Mol Cells 2002; 14: 382-387 [PMID: 12521301]
80. Kondoh N, Hada A, Ryo A, Shuda M, Arai M, Matsubara O, Kimura F, Wakatsuki T, Yamamoto M. Activation of Ga-lectin-1 gene in human hepatocellular carcinoma involves methylation-sensitive complex formations at the transcrip-tional upstream and downstream elements. Int J Oncol 2003; 23: 1575-1583 [PMID: 14612929]
81. Spano D, Russo R, Di Maso V, Rosso N, Terracciano LM, Roncalli M, Tornillo L, Capasso M, Tiribelli C, Iolascon A. Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness. Mol Med 2010; 16: 102-115 [PMID: 20200618 DOI: 10.2119/molmed.2009.00119]
82. Wu H, Chen P, Liao R, Li YW, Yi Y, Wang JX, Sun TW, Zhou J, Shi YH, Yang XR, Jin JJ, Cheng YF, Fan J, Qiu SJ. Overex-pression of galectin-1 is associated with poor prognosis in human hepatocellular carcinoma following resection. J Gas-troenterol Hepatol 2012; 27: 1312-1319 [PMID: 22432916 DOI: 10.1111/j.1440-1746.2012.07130.x]
83. Cimmino F, Schulte JH, Zollo M, Koster J, Versteeg R, Iolas-con A, Eggert A, Schramm A. Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressiveness. Onco-gene 2009; 28: 2015-2023 [PMID: 19363525 DOI: 10.1038/ onc.2009.70]
84. Wu MH, Hong TM, Cheng HW, Pan SH, Liang YR, Hong HC, Chiang WF, Wong TY, Shieh DB, Shiau AL, Jin YT, Chen YL. Galectin-1-mediated tumor invasion and metastasis, up-regulated matrix metalloproteinase expression, and reorganized actin cytoskeletons. Mol Cancer Res 2009; 7: 311-318 [PMID: 19276182 DOI: 10.1158/1541-7786. MCR-08-0297]
85. Espelt MV, Croci DO, Bacigalupo ML, Carabias P, Manzi M, Elola MT, Muñoz MC, Dominici FP, Wolfenstein-Todel C, Rabinovich GA, Troncoso MF. Novel roles of galectin-1 in hepatocellular carcinoma cell adhesion, polarization, and in vivo tumor growth. Hepatology 2011; 53: 2097-2106 [PMID: 21391228 DOI: 10.1002/hep.24294]
86. Garín MI, Chu CC, Golshayan D, Cernuda-Morollón E, Wait R, Lechler RI. Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood 2007; 109: 2058-2065 [PMID: 17110462 DOI: 10.1182/blood-2006-04-016451]
87. Orentas RJ, Kohler ME, Johnson BD. Suppression of anti-cancer immunity by regulatory T cells: back to the future. Semin Cancer Biol 2006; 16: 137-149 [PMID: 16376101 DOI: 10.1016/j.semcancer.2005.11.007]
88. Tiegs G, Hentschel J, Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 1992; 90: 196-203 [PMID: 1634608 DOI: 10.1172/ JCI115836]
89. Santucci L, Fiorucci S, Cammilleri F, Servillo G, Federici B, Morelli A. Galectin-1 exerts immunomodulatory and protective effects on concanavalin A-induced hepatitis in mice. Hepatology 2000; 31: 399-406 [PMID: 10655263 DOI: 10.1002/ hep.510310220]
90. Mauad TH, van Nieuwkerk CM, Dingemans KP, Smit JJ, Schinkel AH, Notenboom RG, Van Den Bergh Weerman MA, Verkruisen RP, Groen AK, Oude Elferink RP. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol 1994; 145: 1237-1245 [PMID: 7977654]
91. Potikha T, Stoyanov E, Pappo O, Frolov A, Mizrahi L, Olam D, Shnitzer-Perlman T, Weiss I, Barashi N, Peled A, Sass G, Tiegs G, Poirier F, Rabinovich GA, Galun E, Goldenberg D. Interstrain differences in chronic hepatitis and tumor development in a murine model of infammation-mediated hepatocarcinogenesis. Hepatology 2013; 58: 192-204 [PMID: 23423643 DOI: 10.1002/hep.26335]
92. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218 [PMID: 15690074 DOI: 10.1172/JCI24282]
93. Kristensen DB, Kawada N, Imamura K, Miyamoto Y, Tate-no C, Seki S, Kuroki T, Yoshizato K. Proteome analysis of rat hepatic stellate cells. Hepatology 2000; 32: 268-277 [PMID: 10915733 DOI: 10.1053/jhep.2000.9322]
94. Maeda N, Kawada N, Seki S, Arakawa T, Ikeda K, Iwao H, Okuyama H, Hirabayashi J, Kasai K, Yoshizato K. Stimulation of proliferation of rat hepatic stellate cells by galectin-1 and galectin-3 through different intracellular signaling pathways. J Biol Chem 2003; 278: 18938-18944 [PMID: 12646584 DOI: 10.1074/jbc.M209673200]
95. Glaser S, Francis H, Demorrow S, Lesage G, Fava G, Marzi-oni M, Venter J, Alpini G. Heterogeneity of the intrahepatic biliary epithelium. World J Gastroenterol 2006; 12: 3523-3536 [PMID: 16773709]
96. Shimonishi T, Miyazaki K, Kono N, Sabit H, Tuneyama K, Harada K, Hirabayashi J, Kasai K, Nakanuma Y. Expression of endogenous galectin-1 and galectin-3 in intrahepatic cholangiocarcinoma. Hum Pathol 2001; 32: 302-310 [PMID: 11274640 DOI: 10.1053/hupa.2001.22767]
97. Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 1996; 93: 6737-6742 [PMID: 8692888]
98. Morris S, Ahmad N, André S, Kaltner H, Gabius HJ, Bre-nowitz M, Brewer F. Quaternary solution structures of galectins-1, -3, and -7. Glycobiology 2004; 14: 293-300 [PMID: 14693909 DOI: 10.1093/glycob/cwh029]
99. Yang RY, Hill PN, Hsu DK, Liu FT. Role of the carboxyl-terminal lectin domain in self-association of galectin-3. Biochemistry 1998; 37: 4086-4092 [PMID: 9521730 DOI: 10.1021/ bi971409c]
100. Ahmad N, Gabius HJ, André S, Kaltner H, Sabesan S, Roy R, Liu B, Macaluso F, Brewer CF. Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J Biol Chem 2004; 279: 10841-10847 [PMID: 14672941 DOI: 10.1074/jbc. M312834200]
101. Newlaczyl AU, Yu LG. Galectin-3--a jack-of-all-trades in cancer. Cancer Lett 2011; 313: 123-128 [PMID: 21974805 DOI: 10.1016/j.canlet.2011.09.003]
102. Gong HC, Honjo Y, Nangia-Makker P, Hogan V, Mazurak N, Bresalier RS, Raz A. The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. Cancer Res 1999; 59: 6239-6245 [PMID: 10626818]
103. Tsay YG, Lin NY, Voss PG, Patterson RJ, Wang JL. Export of galectin-3 from nuclei of digitonin-permeabilized mouse 3T3 fibroblasts. Exp Cell Res 1999; 252: 250-261 [PMID: 10527616 DOI: 10.1006/excr.1999.4643]
104. Funasaka T, Balan V, Raz A, Wong RW. Nucleoporin Nup98 mediates galectin-3 nuclear-cytoplasmic trafficking. Biochem Biophys Res Commun 2013; 434: 155-161 [PMID: 23541576 DOI: 10.1016/j.bbrc.2013.03.052]
105. Menon RP, Hughes RC. Determinants in the N-terminal domains of galectin-3 for secretion by a novel pathway circumventing the endoplasmic reticulum-Golgi complex. Eur J Biochem 1999; 264: 569-576 [PMID: 10491105]
106. Elad-Sfadia G, Haklai R, Balan E, Kloog Y. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J Biol Chem 2004; 279: 34922-34930 [PMID: 15205467 DOI: 10.1074/jbc.M312697200]
107. Shalom-Feuerstein R, Cooks T, Raz A, Kloog Y. Galectin-3 regulates a molecular switch from N-Ras to K-Ras usage in human breast carcinoma cells. Cancer Res 2005; 65: 7292-7300 [PMID: 16103080 DOI: 10.1158/0008-5472.CAN-05-0775]
108. Lee YJ, Song YK, Song JJ, Siervo-Sassi RR, Kim HR, Li L, Spitz DR, Lokshin A, Kim JH. Reconstitution of galectin-3 alters glutathione content and potentiates TRAIL-induced cytotoxicity by dephosphorylation of Akt. Exp Cell Res 2003; 288: 21-34 [PMID: 12878156]
109. Oka N, Nakahara S, Takenaka Y, Fukumori T, Hogan V, Kanayama HO, Yanagawa T, Raz A. Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-in-duced apoptosis by activating Akt in human bladder carcinoma cells. Cancer Res 2005; 65: 7546-7553 [PMID: 16140916 DOI: 10.1158/0008-5472.CAN-05-1197]
110. Dagher SF, Wang JL, Patterson RJ. Identifcation of galec-tin-3 as a factor in pre-mRNA splicing. Proc Natl Acad Sci USA 1995; 92: 1213-1217 [PMID: 7862663]
111. Park JW, Voss PG, Grabski S, Wang JL, Patterson RJ. Association of galectin-1 and galectin-3 with Gemin4 in complexes containing the SMN protein. Nucleic Acids Res 2001; 29: 3595-3602 [PMID: 11522829]
112. Shimura T, Takenaka Y, Fukumori T, Tsutsumi S, Okada K, Hogan V, Kikuchi A, Kuwano H, Raz A. Implication of galectin-3 in Wnt signaling. Cancer Res 2005; 65: 3535-3537 [PMID: 15867344 DOI: 10.1158/0008-5472.CAN-05-0104]
113. Fukumori T, Takenaka Y, Yoshii T, Kim HR, Hogan V, Ino-hara H, Kagawa S, Raz A. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res 2003; 63: 8302-8311 [PMID: 14678989]
114. Hsu DK, Chen HY, Liu FT. Galectin-3 regulates T-cell functions. Immunol Rev 2009; 230: 114-127 [PMID: 19594632 DOI: 10.1111/j.1600-065X.2009.00798.x]
115. Radosavljevic G, Volarevic V, Jovanovic I, Milovanovic M, Pejnovic N, Arsenijevic N, Hsu DK, Lukic ML. The roles of Galectin-3 in autoimmunity and tumor progression. Immunol Res 2012; 52: 100-110 [PMID: 22418727 DOI: 10.1007/ s12026-012-8286-6]
116. Henderson NC, Sethi T. The regulation of infammation by galectin-3. Immunol Rev 2009; 230: 160-171 [PMID: 19594635 DOI: 10.1111/j.1600-065X.2009.00794.x]
117. Califice S, Castronovo V, Van Den Brûle F. Galectin-3 and cancer (Review). Int J Oncol 2004; 25: 983-992 [PMID: 15375548]
118. Fukumori T, Kanayama HO, Raz A. The role of galectin-3 in cancer drug resistance. Drug Resist Updat 2007; 10: 101-108 [PMID: 17544840 DOI: 10.1016/j.drup.2007.04.001]
119. Kadrofske MM, Openo KP, Wang JL. The human LGALS3 (galectin-3) gene: determination of the gene structure and functional characterization of the promoter. Arch Biochem Biophys 1998; 349: 7-20 [PMID: 9439577 DOI: 10.1006/ abbi.1997.0447]
120. Keller S, Angrisano T, Florio E, Pero R, Decaussin-Petrucci M, Troncone G, Capasso M, Lembo F, Fusco A, Chiariotti L. DNA methylation state of the galectin-3 gene represents a potential new marker of thyroid malignancy. Oncol Lett 2013; 6: 86-90 [PMID: 23946782 DOI: 10.3892/ol.2013.1312]
121. Ruebel KH, Jin L, Qian X, Scheithauer BW, Kovacs K, Nakamura N, Zhang H, Raz A, Lloyd RV. Effects of DNA methylation on galectin-3 expression in pituitary tumors. Cancer Res 2005; 65: 1136-1140 [PMID: 15734994 DOI: 10.1158/0008-5472.CAN-04-3578]
122. Margadant C, Van Den Bout I, van Boxtel AL, Thijssen VL, Sonnenberg A. Epigenetic regulation of galectin-3 expression by β1 integrins promotes cell adhesion and migration. J Biol Chem 2012; 287: 44684-44693 [PMID: 23118221 DOI: 10.1074/jbc.M112.426445]
123. Ramasamy S, Duraisamy S, Barbashov S, Kawano T, Khar-banda S, Kufe D. The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol Cell 2007; 27: 992-1004 [PMID: 17889671 DOI: 10.1016/ j.molcel.2007.07.031]
124. Hsu DK, Dowling CA, Jeng KC, Chen JT, Yang RY, Liu FT. Galectin-3 expression is induced in cirrhotic liver and hepa-tocellular carcinoma. Int J Cancer 1999; 81: 519-526 [PMID: 10225438]
125. Luo JH, Ren B, Keryanov S, Tseng GC, Rao UN, Monga SP, Strom S, Demetris AJ, Nalesnik M, Yu YP, Ranganathan S, Michalopoulos GK. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblasto-mas. Hepatology 2006; 44: 1012-1024 [PMID: 17006932 DOI: 10.1002/hep.21328]
126. Matsuda Y, Yamagiwa Y, Fukushima K, Ueno Y, Shi-mosegawa T. Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma. Hepatol Res 2008; 38: 1098-1111 [PMID: 18684128 DOI: 10.1111/j.1872-034X.2008.00387.x]
127. Frachon S, Gouysse G, Dumortier J, Couvelard A, Nejjari M, Mion F, Berger F, Paliard P, Boillot O, Scoazec JY. Endothe-lial cell marker expression in dysplastic lesions of the liver: an immunohistochemical study. J Hepatol 2001; 34: 850-857 [PMID: 11451168]
128. Jia J, Wang J, Teh M, Sun W, Zhang J, Kee I, Chow PK, Liang RC, Chung MC, Ge R. Identifcation of proteins differentially expressed between capillary endothelial cells of he-patocellular carcinoma and normal liver in an orthotopic rat tumor model using 2-D DIGE. Proteomics 2010; 10: 224-234 [PMID: 19899081 DOI: 10.1002/pmic.200900607]
129. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010; 141: 1117-1134 [PMID: 20602996 DOI: 10.1016/j.cell.2010.06.011]
130. Krall JA, Beyer EM, MacBeath G. High- and low-affinity epidermal growth factor receptor-ligand interactions activate distinct signaling pathways. PLoS One 2011; 6: e15945 [PMID: 21264347 DOI: 10.1371/journal.pone.0015945]
131. Hu Z, Jiang X, Xu Y, Lu N, Wang W, Luo J, Zou H, Zheng D, Feng X. Downregulation of galectin-3 by EGF mediates the apoptosis of HepG2 cells. Mol Cell Biochem 2012; 369: 157-165 [PMID: 22761016 DOI: 10.1007/s11010-012-1378-8]
132. Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, Haslett C, Simpson KJ, Sethi T. Galectin-3 regulates myofibroblast activation and hepatic fbrosis. Proc Natl Acad Sci USA 2006; 103: 5060-5065 [PMID: 16549783 DOI: 10.1073/pnas.0511167103]
133. Yamazaki K, Kawai A, Kawaguchi M, Hibino Y, Li F, Sa-sahara M, Tsukada K, Hiraga K. Simultaneous induction of galectin-3 phosphorylated on tyrosine residue, p21(WAF1/ Cip1/Sdi1), and the proliferating cell nuclear antigen at a distinctive period of repair of hepatocytes injured by CCl4. Biochem Biophys Res Commun 2001; 280: 1077-1084 [PMID: 11162637 DOI: 10.1006/bbrc.2000.4193]
134. Jiang JX, Chen X, Hsu DK, Baghy K, Serizawa N, Scott F, Takada Y, Takada Y, Fukada H, Chen J, Devaraj S, Adam-son R, Liu FT, Török NJ. Galectin-3 modulates phagocytosis-induced stellate cell activation and liver fbrosis in vivo. Am J Physiol Gastrointest Liver Physiol 2012; 302: G439-G446 [PMID: 22159281 DOI: 10.1152/ajpgi.00257.2011]
135. Jiao J, Friedman SL, Aloman C. Hepatic fbrosis. Curr Opin Gastroenterol 2009; 25: 223-229 [PMID: 19396960]
136. Wanninger J, Weigert J, Wiest R, Bauer S, Karrasch T, Farkas S, Scherer MN, Walter R, Weiss TS, Hellerbrand C, Neumeier M, Schäffer A, Buechler C. Systemic and hepatic vein galectin-3 are increased in patients with alcoholic liver cirrhosis and negatively correlate with liver function. Cytokine 2011; 55: 435-440 [PMID: 21715185 DOI: 10.1016/ j.cyto.2011.06.001]
137. Junking M, Wongkham C, Sripa B, Sawanyawisuth K, Ara-ki N, Wongkham S. Decreased expression of galectin-3 is associated with metastatic potential of liver fuke-associated cholangiocarcinoma. Eur J Cancer 2008; 44: 619-626 [PMID: 18272359 DOI: 10.1016/j.ejca.2008.01.014]
138. Wongkham S, Junking M, Wongkham C, Sripa B, Chur-In S, Araki N. Suppression of galectin-3 expression enhances apoptosis and chemosensitivity in liver fluke-associated cholangiocarcinoma. Cancer Sci 2009; 100: 2077-2084 [PMID: 19723119 DOI: 10.1111/j.1349-7006.2009.01304.x]
139. Erickson SK. Nonalcoholic fatty liver disease. J Lipid Res 2009; 50 Suppl: S412-S416 [PMID: 19074370 DOI: 10.1194/jlr. R800089-JLR200]
140. Nomoto K, Tsuneyama K, Abdel Aziz HO, Takahashi H, Murai Y, Cui ZG, Fujimoto M, Kato I, Hiraga K, Hsu DK, Liu FT, Takano Y. Disrupted galectin-3 causes non-alcoholic fatty liver disease in male mice. J Pathol 2006; 210: 469-477 [PMID: 17029217 DOI: 10.1002/path.2065]
141. Nakanishi Y, Tsuneyama K, Nomoto K, Fujimoto M, Salunga TL, Nakajima T, Miwa S, Murai Y, Hayashi S, Kato I, Hiraga K, Hsu DK, Liu FT, Takano Y. Nonalcoholic steato-hepatitis and hepatocellular carcinoma in galectin-3 knockout mice. Hepatol Res 2008; 38: 1241-1251 [PMID: 18637146 DOI: 10.1111/j.1872-034X.2008.00395.x]
142. Nomoto K, Nishida T, Nakanishi Y, Fujimoto M, Takasaki I, Tabuchi Y, Tsuneyama K. Defciency in galectin-3 promotes hepatic injury in CDAA diet-induced nonalcoholic fatty liver disease. ScientifcWorldJournal 2012; 2012: 959824 [PMID: 22593713 DOI: 10.1100/2012/959824]
143. Iacobini C, Menini S, Ricci C, Blasetti Fantauzzi C, Scipioni A, Salvi L, Cordone S, Delucchi F, Serino M, Federici M, Pricci F, Pugliese G. Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver. J Hepatol 2011; 54: 975-983 [PMID: 21145823 DOI: 10.1016/j.jhep.2010.09.020]
144. Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT, Cerami A. Identifcation of galectin-3 as a high-affnity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995; 1: 634-646 [PMID: 8529130]
145. Butscheid M, Hauptvogel P, Fritz P, Klotz U, Alscher DM. Hepatic expression of galectin-3 and receptor for advanced glycation end products in patients with liver disease. J Clin Pathol 2007; 60: 415-418 [PMID: 16775125 DOI: 10.1136/ jcp.2005.032391]
146. Lee WM. Acetaminophen-related acute liver failure in the United States. Hepatol Res 2008; 38 Suppl 1: S3-S8 [PMID: 19125949 DOI: 10.1111/j.1872-034X.2008.00419.x]
147. Dragomir AC, Sun R, Mishin V, Hall LB, Laskin JD, Laskin DL. Role of galectin-3 in acetaminophen-induced hepato-toxicity and infammatory mediator production. Toxicol Sci 2012; 127: 609-619 [PMID: 22461450 DOI: 10.1093/toxsci/ kfs117]
148. Dragomir AC, Sun R, Choi H, Laskin JD, Laskin DL. Role of galectin-3 in classical and alternative macrophage activation in the liver following acetaminophen intoxication. J Immunol 2012; 189: 5934-5941 [PMID: 23175698 DOI: 10.4049/jimmu-nol.1201851]
149. Volarevic V, Milovanovic M, Ljujic B, Pejnovic N, Ar-senijevic N, Nilsson U, Leffler H, Lukic ML. Galectin-3 deficiency prevents concanavalin A-induced hepatitis in mice. Hepatology 2012; 55: 1954-1964 [PMID: 22213244 DOI: 10.1002/hep.25542]
150. Huflejt ME, Leffler H. Galectin-4 in normal tissues and cancer. Glycoconj J 2004; 20: 247-255 [PMID: 15115909 DOI: 10.1023/B: GLYC.0000025819.54723.a0]
151. Danielsen EM, Hansen GH. Lipid raft organization and function in the small intestinal brush border. J Physiol Bio-chem 2008; 64: 377-382 [PMID: 19391463]
152. Delacour D, Gouyer V, Zanetta JP, Drobecq H, Leteurtre E, Grard G, Moreau-Hannedouche O, Maes E, Pons A, André S, Le Bivic A, Gabius HJ, Manninen A, Simons K, Huet G. Galectin-4 and sulfatides in apical membrane traffcking in enterocyte-like cells. J Cell Biol 2005; 169: 491-501 [PMID: 15883199 DOI: 10.1083/jcb.200407073]
153. Satelli A, Rao PS, Thirumala S, Rao US. Galectin-4 functions as a tumor suppressor of human colorectal cancer. Int J Cancer 2011; 129: 799-809 [PMID: 21064109 DOI: 10.1002/ ijc.25750]
154. Kondoh N, Wakatsuki T, Ryo A, Hada A, Aihara T, Horiu-chi S, Goseki N, Matsubara O, Takenaka K, Shichita M, Tanaka K, Shuda M, Yamamoto M. Identification and characterization of genes associated with human hepatocel-lular carcinogenesis. Cancer Res 1999; 59: 4990-4996 [PMID: 10519413]
155. Hippo Y, Yashiro M, Ishii M, Taniguchi H, Tsutsumi S, Hirakawa K, Kodama T, Aburatani H. Differential gene expression profles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer Res 2001; 61: 889-895 [PMID: 11221876]
156. Bidon-Wagner N, Le Pennec JP. Human galectin-8 isoforms and cancer. Glycoconj J 2004; 19: 557-563 [PMID: 14758080 DOI: 10.1023/B: GLYC.0000014086.38343.98]
157. Stowell SR, Arthur CM, Slanina KA, Horton JR, Smith DF, Cummings RD. Dimeric Galectin-8 induces phospha-tidylserine exposure in leukocytes through polylactos-amine recognition by the C-terminal domain. J Biol Chem 2008; 283: 20547-20559 [PMID: 18456665 DOI: 10.1074/jbc. M802495200]
158. Hadari YR, Paz K, Dekel R, Mestrovic T, Accili D, Zick Y. Galectin-8. A new rat lectin, related to galectin-4. J Biol Chem 1995; 270: 3447-3453 [PMID: 7852431]
159. Danguy A, Rorive S, Decaestecker C, Bronckart Y, Kaltner H, Hadari YR, Goren R, Zich Y, Petein M, Salmon I, Gabius HJ, Kiss R. Immunohistochemical profle of galectin-8 expression in benign and malignant tumors of epithelial, mesen-chymatous and adipous origins, and of the nervous system. Histol Histopathol 2001; 16: 861-868 [PMID: 11510978]
160. Wada J, Kanwar YS. Identifcation and characterization of galectin-9, a novel beta-galactoside-binding mammalian lec-tin. J Biol Chem 1997; 272: 6078-6086 [PMID: 9038233]
161. Hirabayashi J, Hashidate T, Arata Y, Nishi N, Nakamura T, Hirashima M, Urashima T, Oka T, Futai M, Muller WE, Yagi F, Kasai K. Oligosaccharide specifcity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta 2002; 1572: 232-254 [PMID: 12223272]
162. Sato M, Nishi N, Shoji H, Seki M, Hashidate T, Hirabayashi J, Kasai Ki K, Hata Y, Suzuki S, Hirashima M, Nakamura T. Functional analysis of the carbohydrate recognition domains and a linker peptide of galectin-9 as to eosinophil chemoattractant activity. Glycobiology 2002; 12: 191-197 [PMID: 11971863]
163. Bi S, Earl LA, Jacobs L, Baum LG. Structural features of galectin-9 and galectin-1 that determine distinct T cell death pathways. J Biol Chem 2008; 283: 12248-12258 [PMID: 18258591 DOI: 10.1074/jbc.M800523200]
164. Türeci O, Schmitt H, Fadle N, Pfreundschuh M, Sahin U. Molecular defnition of a novel human galectin which is im-munogenic in patients with Hodgkin's disease. J Biol Chem 1997; 272: 6416-6422 [PMID: 9045665]
165. Hirashima M, Kashio Y, Nishi N, Yamauchi A, Imaizumi TA, Kageshita T, Saita N, Nakamura T. Galectin-9 in physiological and pathological conditions. Glycoconj J 2004; 19: 593-600 [PMID: 14758084 DOI: 10.1023/B: GLYC.000001409 0.63206.2f]
166. Fujihara S, Mori H, Kobara H, Rafq K, Niki T, Hirashima M, Masaki T. Galectin-9 in cancer therapy. Recent Pat En-docr Metab Immune Drug Discov 2013; 7: 130-137 [PMID: 23514536]
167. Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kas-sam N, Lei C, Chandwaskar R, Karman J, Su EW, Hirashima M, Bruce JN, Kane LP, Kuchroo VK, Hafer DA. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 2007; 318: 1141-1143 [PMID: 18006747 DOI: 10.1126/science.1148536]
168. Sánchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX, Sabatos CA, Manlongat N, Bender O, Kamradt T, Kuchroo VK, Gutiérrez-Ramos JC, Coyle AJ, Strom TB. Tim-3 inhibits T helper type 1-mediated auto- and alloim-mune responses and promotes immunological tolerance. Nat Immunol 2003; 4: 1093-1101 [PMID: 14556005 DOI: 10.1038/ni987]
169. Zhu C, Anderson AC, Kuchroo VK. TIM-3 and its regulatory role in immune responses. Curr Top Microbiol Immunol 2011; 350: 1-15 [PMID: 20700701 DOI: 10.1007/82_2010_84]
170. Li Y, Feng J, Geng S, Geng S, Wei H, Chen G, Li X, Wang L, Wang R, Peng H, Han G, Shen B, Li Y. The N- and C-termi-nal carbohydrate recognition domains of galectin-9 contribute differently to its multiple functions in innate immunity and adaptive immunity. Mol Immunol 2011; 48: 670-677 [PMID: 21146220 DOI: 10.1016/j.molimm.2010.11.011]
171. Chou FC, Shieh SJ, Sytwu HK. Attenuation of Th1 response through galectin-9 and T-cell Ig mucin 3 interaction inhibits autoimmune diabetes in NOD mice. Eur J Immunol 2009; 39: 2403-2411 [PMID: 19670381 DOI: 10.1002/eji.200839177]
172. Su EW, Bi S, Kane LP. Galectin-9 regulates T helper cell function independently of Tim-3. Glycobiology 2011; 21: 1258-1265 [PMID: 21187321 DOI: 10.1093/glycob/cwq214]
173. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo VK. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005; 6: 1245-1252 [PMID: 16286920 DOI: 10.1038/ni1271]
174. Leitner J, Rieger A, Pickl WF, Zlabinger G, Grabmeier-Pfistershammer K, Steinberger P. TIM-3 does not act as a receptor for galectin-9. PLoS Pathog 2013; 9: e1003253 [PMID: 23555261 DOI: 10.1371/journal.ppat.1003253]
175. Asakura H, Kashio Y, Nakamura K, Seki M, Dai S, Shirato Y, Abedin MJ, Yoshida N, Nishi N, Imaizumi T, Saita N, Toya-ma Y, Takashima H, Nakamura T, Ohkawa M, Hirashima M. Selective eosinophil adhesion to fbroblast via IFN-gamma-induced galectin-9. J Immunol 2002; 169: 5912-5918 [PMID: 12421975]
176. Imaizumi T, Kumagai M, Sasaki N, Kurotaki H, Mori F, Seki M, Nishi N, Fujimoto K, Tanji K, Shibata T, Tamo W, Matsumiya T, Yoshida H, Cui XF, Takanashi S, Hanada K, Okumura K, Yagihashi S, Wakabayashi K, Nakamura T, Hirashima M, Satoh K. Interferon-gamma stimulates the expression of galectin-9 in cultured human endothelial cells. J Leukoc Biol 2002; 72: 486-491 [PMID: 12223516]
177. Mengshol JA, Golden-Mason L, Arikawa T, Smith M, Niki T, McWilliams R, Randall JA, McMahan R, Zimmerman MA, Rangachari M, Dobrinskikh E, Busson P, Polyak SJ, Hirashima M, Rosen HR. A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS One 2010; 5: e9504 [PMID: 20209097 DOI: 10.1371/journal.pone.0009504]
178. Yoshida H, Imaizumi T, Kumagai M, Kimura K, Satoh C, Hanada N, Fujimoto K, Nishi N, Tanji K, Matsumiya T, Mori F, Cui XF, Tamo W, Shibata T, Takanashi S, Okumura K, Nakamura T, Wakabayashi K, Hirashima M, Sato Y, Satoh K. Interleukin-1beta stimulates galectin-9 expression in human astrocytes. Neuroreport 2001; 12: 3755-3758 [PMID: 11726788]
179. Saita N, Goto E, Yamamoto T, Cho I, Tsumori K, Kohrogi H, Maruo K, Ono T, Takeya M, Kashio Y, Nakamura K, Hirashi-ma M. Association of galectin-9 with eosinophil apoptosis. Int Arch Allergy Immunol 2002; 128: 42-50 [PMID: 12037400]
180. Heusschen R, Griffioen AW, Thijssen VL. Galectin-9 in tumor biology: a jack of multiple trades. Biochim Biophys Acta 2013; 1836: 177-185 [PMID: 23648450 DOI: 10.1016/ j.bbcan.2013.04.006]
181. Zhang ZY, Dong JH, Chen YW, Wang XQ, Li CH, Wang J, Wang GQ, Li HL, Wang XD. Galectin-9 acts as a prognostic factor with antimetastatic potential in hepatocellular carcinoma. Asian Pac J Cancer Prev 2012; 13: 2503-2509 [PMID: 22938412]
182. Nebbia G, Peppa D, Schurich A, Khanna P, Singh HD, Cheng Y, Rosenberg W, Dusheiko G, Gilson R, ChinAleong J, Kennedy P, Maini MK. Upregulation of the Tim-3/ga-lectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS One 2012; 7: e47648 [PMID: 23112829 DOI: 10.1371/journal.pone.0047648]
183. Barjon C, Niki T, Vérillaud B, Opolon P, Bedossa P, Hirashi-ma M, Blanchin S, Wassef M, Rosen HR, Jimenez AS, Wei M, Busson P. A novel monoclonal antibody for detection of galectin-9 in tissue sections: application to human tissues infected by oncogenic viruses. Infect Agent Cancer 2012; 7: 16 [PMID: 22805533 DOI: 10.1186/1750-9378-7-16]
184. Kared H, Fabre T, Bédard N, Bruneau J, Shoukry NH. Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C. PLoS Pathog 2013; 9: e1003422 [PMID: 23818845 DOI: 10.1371/journal. ppat.1003422]
185. Ji XJ, Ma CJ, Wang JM, Wu XY, Niki T, Hirashima M, Moorman JP, Yao ZQ. HCV-infected hepatocytes drive CD4+ CD25+ Foxp3+ regulatory T-cell development through the Tim-3/Gal-9 pathway. Eur J Immunol 2013; 43: 458-467 [PMID: 23161469 DOI: 10.1002/eji.201242768]
186. Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X, Liu J, Shi L, Liu C, Wang G, Zou W. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 2012; 56: 1342-1351 [PMID: 22505239 DOI: 10.1002/hep.25777]
187. Zwacka RM, Zhang Y, Halldorson J, Schlossberg H, Dudus L, Engelhardt JF. CD4(+) T-lymphocytes mediate ischemia/ reperfusion-induced inflammatory responses in mouse liver. J Clin Invest 1997; 100: 279-289 [PMID: 9218504 DOI: 10.1172/JCI119533]
188. Jaeschke H, Farhood A. Neutrophil and Kupffer cell-induced oxidant stress and ischemia-reperfusion injury in rat liver. Am J Physiol 1991; 260: G355-G362 [PMID: 2003603]
189. Hanschen M, Zahler S, Krombach F, Khandoga A. Reciprocal activation between CD4+ T cells and Kupffer cells during hepatic ischemia-reperfusion. Transplantation 2008; 86: 710-718 [PMID: 18791453 DOI: 10.1097/TP.0b013e3181821aa7]
190. Uchida Y, Ke B, Freitas MC, Yagita H, Akiba H, Busuttil RW, Najafian N, Kupiec-Weglinski JW. T-cell immuno-globulin mucin-3 determines severity of liver ischemia/ reperfusion injury in mice in a TLR4-dependent manner. Gastroenterology 2010; 139: 2195-2206 [PMID: 20637206 DOI: 10.1053/j.gastro.2010.07.003]
191. Lv K, Zhang Y, Zhang M, Zhong M, Suo Q. Galec-tin-9 ameliorates Con A-induced hepatitis by inducing CD4(+)CD25(low/int) effector T-Cell apoptosis and increasing regulatory T cell number. PLoS One 2012; 7: e48379 [PMID: 23118999 DOI: 10.1371/journal.pone.0048379]
192. Liberal R, Grant CR, Holder BS, Ma Y, Mieli-Vergani G, Vergani D, Longhi MS. The impaired immune regulation of autoimmune hepatitis is linked to a defective galec-tin-9/tim-3 pathway. Hepatology 2012; 56: 677-686 [PMID: 22371007 DOI: 10.1002/hep.25682]
193. Ronchi F, Falcone M. Immune regulation by invariant NKT cells in autoimmunity. Front Biosci 2008; 13: 4827-4837 [PMID: 18508548]
194. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today 2000; 21: 573-583 [PMID: 11094262]
195. Tang ZH, Liang S, Potter J, Jiang X, Mao HQ, Li Z. Tim-3/ galectin-9 regulate the homeostasis of hepatic NKT cells in a murine model of nonalcoholic fatty liver disease. J Immunol 2013; 190: 1788-1796 [PMID: 23296703 DOI: 10.4049/jimmu-nol.1202814]
196. Glinskii OV, Sud S, Mossine VV, Mawhinney TP, Anthony DC, Glinsky GV, Pienta KJ, Glinsky VV. Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/ galectin-3 inhibitor lactulose-L-leucine. Neoplasia 2012; 14: 65-73 [PMID: 22355275]
197. Liu HY, Huang ZL, Yang GH, Lu WQ, Yu NR. Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model. World J Gastroenterol 2008; 14: 7386-7391 [PMID: 19109874]
198. Nangia-Makker P, Hogan V, Honjo Y, Baccarini S, Tait L, Bresalier R, Raz A. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 2002; 94: 1854-1862 [PMID: 12488479]